Sistemic announces availability new SistemRNA Technology

Sistemic today announced immediate availability new SistemRNA™ product lines in key therapeutic areas including oncology and inflammation. These new product additions will strengthen strategic decision making at critical stages of the drug discovery and development process, helping to realise the full value of client's compound assets. This announcement comes following their recent news of expansion into the US market with headquarters located in Boston.

“The validity of our use of microRNA profiling as a sentinel marker of phenotypic effects in model systems is overwhelming, and we are seeing time and time again very strong correlations between microRNA changes and drug effects”

Instead of the traditional target-orientated approach, SistemRNA™ Technology uses a compound-centric approach. This involves identifying drug effects by associative changes in microRNA expression profiles and their analysis in context against a growing proprietary database of known drug responses. Client compounds can then be characterized on the basis of indication, mechanism of action and adverse effects. "The validity of our use of microRNA profiling as a sentinel marker of phenotypic effects in model systems is overwhelming, and we are seeing time and time again very strong correlations between microRNA changes and drug effects" stated Dr Vincent O'Brien, CSO.

The new oncology and inflammation products will be of value to pharmaceutical and biotechnology companies that are seeking to position new compounds or reposition existing compounds in these therapeutic areas. Launched in response to customer demand, the oncology platform knowledgebase contains eight major drug classes, including HDACi, with five or more representatives from each class. Prof. Chris Hillier, CEO of Sistemic commented "The strength of Sistemic's approach is that we provide an extremely reliable way to make key decisions on safety and efficacy based on very strong biological information about the properties of your compound without reference to the expected target. This lack of bias produces valuable evidence to support drug development and has the power to create some very exciting opportunities."

SOURCE Sistemic